Press release

April 2021

Scilex Holding, A Subsidiary of Sorrento, Has Received From FDA a sNDA Approval for Ztlido® Label Expansion

April 9, 2021

Palo Alto, California, April 9, 2021 — Scilex Holding (“Scilex”), an over 99% owned subsidiary of Sorrento Therapeutics (NASDAQ: SRNE, “Sorrento”), has received a supplemental new drug application (sNDA) approval from the FDA for ZTlido® to make efficacy labeling change with clinical data. ZTlido® is the only lidocaine topical system that has been studied under … Continue reading Scilex Holding, A Subsidiary of Sorrento, Has Received From FDA a sNDA Approval for Ztlido® Label Expansion
X

Share This Page

XS SM MD LG XL